Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atrasentan in hormone naive prostate cancer with biochemical failure
NCT00038662Phase 2Completed
- Sponsor
- Abbott Laboratories
- Start
- May 2002
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in prostate cancer (PCa) comparing Atrasentan 10 mg with Placebo (2 arms). Primary endpoint: Rate of rise in PSA. Started May 2002; status: completed.
02
Drugs
atrasentan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00038662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00038662.